Anti-IL-6 antibody treatment in late-stage cachexia has been unsuccessful in clinical trials involving participants with non-small-cell lung cancer, and the pleiotropic effects of IL-6 might lead to side effects such as an increased risk of infections. This evidence concerns the gene IL6 and infection.